Ascendis Pharma vs Neurocrine Biosciences

Ascendis Pharma (ASND), health care, and Neurocrine Biosciences (NBIX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Ascendis Pharma is worth $17.8B on the stock market and Neurocrine Biosciences $16.8B: Ascendis Pharma is valued at 6% more. Ascendis Pharma trades at 17.8 times earnings and Neurocrine Biosciences at 24.6; operating margins in their latest fiscal years were -18.9% and 21.6%. Over the past year Ascendis Pharma's share price has moved +25.1% and Neurocrine Biosciences's +19.2%.

Key facts

Ascendis Pharma market value
$17.8B
Neurocrine Biosciences market value
$16.8B
Ascendis Pharma P/E
17.8
Neurocrine Biosciences P/E
24.6
Ascendis Pharma revenue
$799MFY to 2025-12-31
Neurocrine Biosciences revenue
$2.9BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Ascendis Pharma vs Neurocrine Biosciences: every measure side by side
Measure Ascendis Pharma Neurocrine Biosciences
SectorHealth CareHealth Care
Country Denmark United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$17.8Bhigher$16.8Blower
Revenue$799Mlower$2.9Bhigher
Earnings-$253Mlower$478.6Mhigher
Employees1,189lower2,500higher
Total assets$1.4Blower$4.6Bhigher
Valuation
P/E17.8lower24.6higher
P/S22.3higher5.9lower
P/B—4.3
Dividend yield—0.00%
Profitability
Operating margin-18.9%lower21.6%higher
Balance sheet
Net assets-$180.7Mlower$3.3Bhigher
Total liabilities$1.6Bhigher$1.4Blower
Total debt$799.1M—
Cash on hand$683.5Mlower$713Mhigher
Price change
Today-0.20%lower+0.37%higher
1 year+25.1%higher+19.2%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Ascendis Pharma only (2)

Percentages are each holding's share of that investor's reported portfolio. Who owns ASND · Who owns NBIX

Further comparisons

Learn

Questions and answers

Which is bigger, Ascendis Pharma or Neurocrine Biosciences?

By market value, Ascendis Pharma is the larger: $17.8B against $16.8B for Neurocrine Biosciences. By revenue in its latest fiscal year, Neurocrine Biosciences is the larger: $2.9B against $799M for Ascendis Pharma.

Which has the higher P/E ratio?

Neurocrine Biosciences: 24.6, against 17.8 for Ascendis Pharma. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Neurocrine Biosciences: 21.6%, against -18.9% for Ascendis Pharma. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Ascendis Pharma and Neurocrine Biosciences?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Ascendis Pharma and 5 hold Neurocrine Biosciences.

Cite this page

Funkfolio, “Ascendis Pharma vs Neurocrine Biosciences”, data as of 18 November 2026. https://funkfolio.com/compare/asnd-vs-nbix

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.